|
|
|
|
Immunostimulant effects against infection --
|
2006
|
1
|
|
|
Immunostimulation with Cytokines in Patients with 'Immunoparalysis' / / H. D. Volk, P. Reinke and W. D. Docke --
|
2000
|
1
|
|
|
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
|
2016
|
1
|
|
|
Immunosuppressants / / Valerie F. J. Quesniaux and Goetz Baumann --40.
|
1994
|
1
|
|
|
The immunosuppressed patient --
|
2002
|
1
|
|
|
The immunosuppressed patient -- Pregnancy --
|
2013
|
1
|
|
|
Immunosuppression --
|
|
3
|
|
|
Immunosuppression dosing in obese solid organ transplant recipients / / B. Andrew Mardis, Caitlin R. Mardis, and Nicole A. Pilch --
|
2016
|
1
|
|
|
Immunosuppression for human corneal graft rejection -- / 12.
|
2004
|
1
|
|
|
Immunosuppression in pediatric liver transplant / / Patrick McKiernan and Ellen Mitchell --32.
|
2019
|
1
|
|
|
Immunosuppression in Solid-Organ Transplantation --
|
2012
|
1
|
|
|
Immunosuppression in the ERA of Biological Agents / / Josep M. Grinyó, Josep M. Cruzado, Oriol Bestard, J.R. Vidal Castiñeira and Joan Torras --
|
2012
|
1
|
|
|
Immunosuppression : new research
|
2009
|
1
|
|
|
Immunosuppression-Related Malignancies -- / Chapter 49
|
2005
|
1
|
|
|
Immunosuppression: the global picture / / K.V. Narayanan Menon, Russell H. Wiesner --
|
2007
|
1
|
|
|
Immunosuppressive agents and monitoring in long-term survivors / / Paul Shaughnessy and Helen Leather --
|
2013
|
1
|
|
|
Immunosuppressive Agents in Pediatric Heart Transplantation / / Indira A. Khimji, Traci M. Kazmerski, and Steven A. Webber --
|
2008
|
1
|
|
|
Immunosuppressive and immunomodulatory drugs -- / Section VII:
|
2021
|
1
|
|
|
Immunosuppressive Drugs, Immunophilins, and Functional Expression of NCX Isoforms --
|
2013
|
1
|
|
|
Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses / / Mouldy Sioud, Anne Mobergslien, and Stein Sæbøe-Larssen --
|
2015
|
1
|
|
|
Immunosuppressive Medications / / Donald Berry and Brian Feingold --
|
2013?
|
1
|
|
|
Immunosuppressive Properties of Mesenchymal Stromal Cells / / Francesco Lanza, Diana Campioni, Endri Mauro, Annalisa Pasini and Roberta Rizzo --
|
2012
|
1
|
|
|
Immunosuppressive properties of the pigmented epithelial cells and subretinal space / / P. Zamiri, S. Sugita, J.W. Streilein --
|
2007
|
1
|
|
|
Immunosuppressives : advancements, applications and analyses
|
2017
|
1
|
|
|
Immunosuppresssion and Immune Escape in Liver Cancer / / Qingqing Wang, Xuetao Cao --
|
2012
|
1
|
|
|
Immunotargeting of the Pulmonary Endothelium via Angiotensin-Converting-Enzyme in Isolated Ventilated and Perfused Human Lung / / Kai Nowak, Hans C. Kölbel, Roman P. Metzger, Christine Hanusch and Marc Frohnmeyer, et al. --
|
2013
|
1
|
|
|
Immunotargeting: The Selective Elimination of Specific Cell Populations with Immunoconjugates / / George L. Mayers --28.
|
1994
|
1
|
|
|
ImmunoTargets and therapy
|
|
1
|
|
|
ImmunoTargets ther
|
|
1
|
|
|
Immunotargets Ther
|
|
1
|
|
|
Immunotechnology
|
1999
|
1
|
|
|
Immunotechnology - antibodies as tools
|
2000
|
1
|
|
|
Immunotechnology (Online)
|
1999
|
1
|
|
|
Immunother Adv
|
2021
|
1
|
|
|
Immunother. insights
|
|
1
|
|
|
Immunother. wkly. (Online)
|
|
1
|
|
|
Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG ODN) in malignant glioma / / Renata Ursu and Antoine F. Carpentier --
|
2012
|
1
|
|
|
Immunotherapeutic strategies for the treatment of glioma
|
2022
|
1
|
|
|
Immunothérapie des cancers au troisième millénaire
|
2014
|
1
|
|
|
Immunotherapies for allergic disease
|
2020
|
1
|
|
|
Immunotherapies for Brain Cancer: From Preclinical Models to Human Trials
|
2014
|
1
|
|
|
Immunotherapies in CLL --
|
2013
|
1
|
|
|
Immunotherapy --
|
|
7
|
|
|
Immunotherapy -- a novel facet of modern therapeutics
|
2021
|
1
|
|
|
Immunotherapy : activation, suppression, and treatments
|
2010
|
1
|
|
|
Immunotherapy advances
|
2021
|
1
|
|
|
Immunotherapy Adverse Events --
|
2022
|
1
|
|
|
Immunotherapy against lung cancers : emerging opportunities and challenges
|
2024
|
1
|
|
|
Immunotherapy and biomarkers in neurodegenerative disorders
|
2016
|
1
|
|
|
Immunotherapy and nanovaccines --
|
2020
|
1
|
 Add Marked to Bag
Add All On Page
 Add Marked to My Lists
|